Detalhe da pesquisa
1.
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(3): 339-351, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30795951
2.
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Lancet
; 386(9992): 433-43, 2015 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26040499
3.
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Lancet Oncol
; 12(7): 631-41, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21641868
4.
Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial.
BMC Cancer
; 11: 373, 2011 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-21864402
5.
Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.
Onkologie
; 32(1-2): 18-24, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19209014
6.
Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
Anticancer Res
; 35(1): 517-21, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25550597